

**NOTICE OF NEW HAMPSHIRE MEDICAID  
DRUG USE REVIEW BOARD  
PUBLIC HEARING  
October 19, 2011**

The New Hampshire Drug Use Review (DUR) Board invites you to attend a public hearing at 3:00 p.m., on October 19, 2011 at the Brown Building – Auditorium, 129 Pleasant Street, Concord, NH. A DUR meeting will immediately follow this public hearing.

The purpose of the public hearing on October 19, 2011, is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 3:00 p.m. and end no later than 4:00 p.m. The DUR meeting will begin at or before 4:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the October 19, 2011 public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

**DRUG USE REVIEW BOARD MEETING  
October 19, 2011  
Meeting Agenda**

I. Old Business

- a. Minutes – 06/15/11 review

II. New Business

1. Review of Current Preferred Drug List Therapeutic Classes with No Proposed Changes

Gastrointestinal

- Hepatitis C
- Ulcerative Colitis
- Proton Pump Inhibitors

Antibiotics

- Macrolides

Miscellaneous

- Topical Androgenic
- Skeletal Muscle Relaxants

Behavioral Health

- Atypical Antipsychotics

Antiparkinson's Agents

- Dopamine Receptor Agonists

Immunologic

- Systemic Immunomodulators

Osteoporosis

- Nasal Calcitonins

Otic Antibiotics

- Quinolones and Combinations

Hematologic

- Hematopoietic Agents

2. Review of Current Preferred Drug List Therapeutic Classes with Proposed Changes
  - Topical Combination Benzoyl Peroxide & Clindamycin Products® (rename to Topical Combination Acne Agents)
3. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes
  - Xenical®
  - Xolair®
4. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
  - Fibromyalgia
  - Combination Benzoyl Peroxide and Clindamycin (rename to Topical Combination Acne Agents)
  
5. Review of New Proposed Clinical Prior Authorization Criteria
  - Hepatitis C
  - Restless Leg Syndrome
  
6. Overview of Drug Utilization Patterns for New Hampshire Medicaid
  - Prospective DUR Reports
  - Utilization Reports
  - Retrospective DUR Reports

### III. Adjourn

Further information regarding the agenda items may be obtained after September 28, 2011, by contacting Robin Calley, at 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: [rlcalley@dhhs.state.nh.us](mailto:rlcalley@dhhs.state.nh.us).

Notice of intent to testify at the October 19, 2011 public hearing, and/or submittal of written comments, should be directed to Robin Calley, Office of Medicaid Business and Policy, 129 Pleasant Street, Concord, NH, 03301, 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: [rlcalley@dhhs.state.nh.us](mailto:rlcalley@dhhs.state.nh.us).